The use of immune checkpoint inhibitors (ICIs) is also supported by the increased expression of PD‐L1/PD‐1 in tumor‐infiltrating lymphocytes from patients with lymphoma and increased PD‐1 expression in circulating T cells from patients with CLL.11 The gene discussed is CD274; the disease is lymphoma.